# A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)

> **NCT06306339** · PHASE2 · UNKNOWN · sponsor: **ImmuneMed, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Moderate to Severe Rheumatoid Arthritis

## Interventions

- **DRUG:** Burfiralimab
- **DRUG:** SOC (Standard of care)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06306339
- **Lead sponsor:** ImmuneMed, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03
- **Primary completion:** 2025-05
- **Final completion:** 2025-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06306339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06306339, "A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06306339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*